Detalhe da pesquisa
1.
Redefining outcomes in immune TTP: an international working group consensus report.
Blood
; 137(14): 1855-1861, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33529333
2.
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
Blood
; 138(17): 1583-1589, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34133718
3.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32693406
4.
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies.
Clin Chem Lab Med
; 61(12): 2115-2130, 2023 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37477188
5.
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
N Engl J Med
; 380(4): 335-346, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30625070
6.
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Blood
; 136(2): 199-209, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325491
7.
Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era.
Ann Hematol
; 101(1): 59-67, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34642787
8.
Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.
Transfus Apher Sci
; 61(3): 103342, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34969586
9.
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.
Lancet Oncol
; 22(3): e119-e130, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545067
10.
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Br J Haematol
; 192(3): 522-530, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32501528
11.
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
Blood
; 133(25): 2664-2668, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31010846
12.
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Ann Hematol
; 100(7): 1769-1778, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33885924
13.
Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?
Transpl Infect Dis
; 23(4): e13602, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728702
14.
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
J Clin Apher
; 36(4): 563-573, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33780553
15.
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1630-1642, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33129376
16.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Blood
; 131(3): 301-310, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150421
17.
Therapeutic plasma exchange: Review of current indications.
Transfus Apher Sci
; 58(3): 247-253, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023623
18.
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Blood
; 127(23): 2833-40, 2016 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091875
19.
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Blood
; 127(9): 1151-62, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26668134
20.
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Blood
; 138(19): 1901-1905, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329372